Company Filing History:
2 out of 10 
1 out of 100 
1 out of 1 Years Active: 2001-2010
Title: Martin Kantlehner: Innovator in Integrin-Inhibitor Compounds
Introduction
Martin Kantlehner is a notable inventor based in Freising, Germany. He has made significant contributions to the field of biochemistry, particularly in the development of peptide and peptide mimetic conjugates with integrin-inhibitor properties. With a total of five patents to his name, his work has the potential to impact various medical treatments.
Latest Patents
Kantlehner's latest patents include innovative compounds designed to serve as integrin inhibitors. One of his inventions relates to compounds of the formula (1) B-Q-X, where B is a bioactive cell adhesive mediating molecule. These compounds can be utilized for treating illnesses such as osteoporosis, thrombosis, cardiac infarction, and arteriosclerosis. Another patent focuses on peptide and peptide mimetic derivatives that also function as integrin inhibitors, further emphasizing their therapeutic potential in addressing deficiencies and inflammations caused by implants.
Career Highlights
Throughout his career, Martin Kantlehner has worked with prominent companies in the pharmaceutical and biotechnology sectors. Notable among these are Biomet Deutschland GmbH and Merck Patent Gesellschaft mit beschränkter Haftung. His experience in these organizations has contributed to his expertise in developing innovative medical solutions.
Collaborations
Kantlehner has collaborated with esteemed colleagues, including Berthold Nies and Horst Kessler. These partnerships have likely enriched his research and development efforts, leading to the successful creation of his patented compounds.
Conclusion
Martin Kantlehner stands out as a significant figure in the realm of biochemistry, particularly for his work on integrin-inhibitor compounds. His contributions have the potential to advance medical treatments and improve patient outcomes.